SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                   FORM 10-QSB


|X|   QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934

                  For the quarterly period ended June 30, 2005

|_|   TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934

      For the transition period from _______________ to _________________


                        Commission file number: 000-32253

                               SECURED DATA, INC.
                               ------------------
           (Name of Small Business Issuer as specific in its Charter)

           Nevada                                         87-0650264
-------------------------------            ------------------------------------
(State or Other Jurisdiction of            (I.R.S. Employer Identification No.)
Incorporation or Organization)

                   16B/F Ruixin Road Bldg. No. 25 Gaoxin Road
                      Xi An 710075 Shaanxi Province, China
              -----------------------------------------------------
           (Address of Principal Executive Offices Including Zip Code)


Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. |X| Yes |_| No

The number of shares outstanding of the registrant's common equity as of June
30, 2005, was 93,604,958 shares of common stock, par value $0.001.

Transitional Small Business Disclosure Format (Check one): |_| Yes |X| No


                                       1
<PAGE>

                               SECURED DATA, INC.
                            INDEX TO THE FORM 10-QSB
                     FOR THE SIX MONTHS ENDED JUNE 30, 2005


                                TABLE OF CONTENTS


PART I.  FINANCIAL INFORMATION

Item 1.  Financial Statements

         Condensed Consolidated Balance Sheet as of June 30, 2005 (unaudited)

         Condensed Consolidated Statements of Operations for the three and
         six-months ended June 30, 2005 (unaudited)

         Condensed Consolidated Statements of Cash Flows for the six-months
         ended June 30, 2005 (unaudited)

         Notes to Condensed Consolidated Financial Statements

Item 2.  Management's Discussion and Analysis or Plan of Operation

Item 3.  Controls and Procedures

PART II. OTHER INFORMATION

Item 1.  Legal Proceedings

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

Item 3.  Defaults Upon Series Securities

Item 4.  Submission of Matters to a Vote of Security Holders

Item 5.  Other Information

Item 6:  Exhibits and Reports on Form 8-K

SIGNATURES


                                       2
<PAGE>

PART I.  FINANCIAL INFORMATION

Item 1.  Financial Statements

                       SECURED DATA, INC. AND SUBSIDIARIES
                      CONDENSED CONSOLIDATED BALANCE SHEET
                         AS OF JUNE 30, 2005 (UNAUDITED)


<TABLE>
<CAPTION>
                                     ASSETS

<S>                                                                   <C>
CURRENT ASSETS
    Cash and cash equivalents                                         $    343,758
    Accounts receivable                                                    462,158
    Inventories, net                                                     1,431,090
    Loans receivable                                                       422,705
    Tax receivable                                                          13,094
    Due from stockholders                                                  258,290
    Other receivables                                                      337,059
                                                                      ------------
        Total Current Assets                                             3,268,154

PROPERTY AND EQUIPMENT, NET                                              2,355,933

LAND USE RIGHTS, NET                                                       132,601
                                                                      ------------
TOTAL ASSETS                                                          $  5,756,688
                                                                      ------------


                      LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
    Accounts payable                                                  $     88,988
    Other payables and accrued expenses                                    109,243
    Income tax and other tax payables                                       25,787
    Convertible note payable                                             1,900,000
    Due to stockholders                                                      1,208
                                                                      ------------
        Total Current Liabilities                                        2,125,226
                                                                      ------------

COMMITMENTS AND CONTINGENCIES                                                   --

MINORITY INTEREST                                                          468,607
                                                                      ------------

STOCKHOLDERS' EQUITY
    Preferred stock, $0.001 par value, 5,000,000 shares authorized,
        non issued and outstanding                                              --
    Common stock, $0.001 par value, 100,000,000 shares authorized,
        93,604,958 shares issued and outstanding                            93,605
    Additional paid-in capital                                           4,998,849
    Retained earnings (deficit)
      Unappropriated                                                    (1,936,849)
      Appropriated                                                           7,250
                                                                      ------------
        Total Stockholders' Equity                                       3,631,462
                                                                      ------------

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                            $  5,756,688
                                                                      ------------
</TABLE>

    The accompanying notes are an integral part of these financial statements


                                       3
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
                                  (UNAUDITED)



<TABLE>
<CAPTION>
                                                 For the Three     For the Three     For the Six       For the Six
                                                 Months Ended      Months Ended      Months Ended      Months Ended
                                                 June 30, 2005     June 30, 2004     June 30, 2005     June 30, 2004
                                                 --------------    --------------    --------------    --------------
<S>                                              <C>               <C>               <C>               <C>
NET SALES                                        $      416,274    $      679,893    $    1,342,812    $    1,213,512

COST OF SALES                                          (276,888)         (619,976)       (1,093,703)       (1,082,062)
                                                 --------------    --------------    --------------    --------------

GROSS PROFIT                                            139,386            59,917           249,109           131,450
                                                 --------------    --------------    --------------    --------------

OPERATING EXPENSES
    Selling expenses and distribution expenses           32,311             8,481            48,705            16,003
    General and administrative expenses                  45,674             5,774            87,750            14,574
    Depreciation and amortization                        17,377             8,290            34,770            21,277
                                                 --------------    --------------    --------------    --------------
           Total Operating Expenses                      95,362            22,545           171,225            51,854
                                                 --------------    --------------    --------------    --------------

INCOME FROM OPERATIONS                                   44,024            37,372            77,884            79,596

OTHER INCOME (EXPENSE)
    Equity in loss of affiliate                              --                --              (112)               --
    Goodwill written off                                 (2,764)               --            (2,764)               --
    Interest income (expense), net                        7,588              (529)            7,637              (363)
    Other income (expense), net                              --                --            42,270            (1,107)
                                                 --------------    --------------    --------------    --------------
           Total Other Income (expense)                   4,824              (529)           47,031            (1,470)

INCOME FROM OPERATIONS BEFORE TAXES AND
                                                 --------------    --------------    --------------    --------------
    MINORITY INTEREST                                    48,848            36,843           124,915            78,126

INCOME TAX EXPENSE                                           --            (4,692)          (25,812)          (18,741)

MINORITY INTEREST                                         3,313             2,077             5,396             4,187
                                                 --------------    --------------    --------------    --------------

NET INCOME                                               52,161            34,228           104,499            63,572

OTHER COMPREHENSIVE INCOME
    Foreign currency translation loss                        --                --                --                --
                                                 --------------    --------------    --------------    --------------

COMPREHENSIVE INCOME                             $       52,161    $       34,228    $      104,499    $       63,572
                                                 --------------    --------------    --------------    --------------

Net income per share - diluted                   $           --    $           --    $           --    $           --
                                                 --------------    --------------    --------------    --------------

Weighted average number of shares outstanding
    during the period - diluted                      93,604,958        80,735,590        93,604,958        80,735,590
                                                 --------------    --------------    --------------    --------------
</TABLE>

    The accompanying notes are an integral part of these financial statements


                                       4
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                                           For the Six        For the Six
                                                                           Months Ended      Months Ended
                                                                          June 30, 2005     June 30, 2004
                                                                          --------------    --------------
<S>                                                                       <C>                <C>
CASH FLOWS FROM OPERATING ACTIVITIES
    Net income                                                                   104,499            63,572
    Adjusted to reconcile net income to net cash provided
       by (used in) operating activities:
       Depreciation and amortization - cost of sales                              68,050            30,750
       Depreciation and amortization                                              34,770            21,277
       Equity in loss of affiliate                                                31,190                --
       Minority interest                                                         409,692            (4,187)
    Changes in operating assets and liabilities (Increase) decrease in:
       Accounts receivable, net                                                 (358,014)          179,407
       Inventories                                                              (129,065)          (29,497)
       Tax receivable                                                            (13,094)               --
       Other receivables                                                          (2,001)         (647,966)
       Increase (decrease) in:
       Accounts payable                                                           32,534             1,501
       Other payables and accrued expenses                                       (35,948)            5,475
       Value added tax payable                                                   (12,323)           20,371
       Income tax and other taxes payable                                         19,103            14,126
                                                                          --------------    --------------
       Net cash provided by (used) in operating activities                       149,393          (345,171)
                                                                          --------------    --------------

CASH FLOWS FROM INVESTING ACTIVITIES
    Decrease in notes receivable                                                      --           506,774
    (Increase) decrease in due from stockholders                                (195,797)              249
    Purchase of property and equipment                                        (1,577,877)           (2,886)
                                                                          --------------    --------------
       Net cash (used in) provided by investing activities                    (1,773,674)          504,137
                                                                          --------------    --------------

CASH FLOWS FROM FINANCING ACTIVITIES
    Registered capital appropriation                                           2,415,458                --
    Increase in loans receivable                                                (422,705)               --
    Decrease in notes payable                                                         --          (241,642)
    Decrease in due to stockholders                                             (192,225)               --
                                                                          --------------    --------------
       Net cash provided by (used in) financing activities                     1,800,528          (241,642)
                                                                          --------------    --------------

NET INCREASE (DECREASE) IN CASH AND CASH
    EQUIVALENTS                                                                  176,247           (82,676)

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD                                 167,511            95,803
                                                                          --------------    --------------

CASH AND CASH EQUIVALENTS AT END OF PERIOD                                       343,758            13,127
                                                                          --------------    --------------

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

Cash paid during the year for:
    Income taxes                                                          $           --    $           --
                                                                          --------------    --------------

    Interest expenses                                                     $           --    $           --
                                                                          --------------    --------------
</TABLE>

    The accompanying notes are an integral part of these financial statements


                                       5
<PAGE>

                               SECURED DATA, INC.

              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (UNAUDITED)
                                 June 30, 2005
 ------------------------------------------------------------------------------

NOTE 1            ORGANIZATION AND BASIS OF PRESENTATION

Secured Data, Inc. ("Secured Data") was incorporated in Nevada on March 16, 2000
under the name Enternet, Inc. On May 23, 2002, the Articles of Incorporation
were amended to change the name of the Company to Secured Data, Inc.

Northwest Bio-Technic Inc. ("Northwest") was incorporated in the British Virgin
Islands ("BVI") on June 25, 2004. Xian Huifeng Biochemistry Joint-Stock Company
Limited ("Huifeng Biochemistry") was incorporated in the People's Republic of
China ("PRC") on January 20, 2000 as a company with limited liabilities and was
restructured as a joint stock company on September 29, 2002 under the laws of
the PRC.

Huifeng Biochemistry produces plant extracts and bio-chemical products used as
pharmaceutical raw materials in the PRC. Most of its products are distributed
within the PRC and some European countries.

On August 23, 2001, Huifeng Biochemistry established a 70% owned subsidiary,
Xian Huifeng Biochemistry Engineering Company Limited ("Huifeng Engineering") in
the PRC with a registered capital of $265,778. The subsidiary has no operations
since its incorporation.

On June 16, 2004 Huifeng Biochemistry acquired an 86.7% interest in Baoji Jisen
Pharmaceutical Company Limited, later renamed to Xian Huifeng Pharmaceutical
Company Limited ("Huifeng Pharmaceutical"), a limited liability company in the
PRC. On November 10, 2004 Huifeng Pharmaceutical increased its registered
capital from $181,159 to $603,865. The increased registered capital was fully
subscribed by a stockholder of the Company, diluting the Company's interest
Huifeng Pharmaceutical from 86.7% to 26%. On May 27, 2005 the PRC Government
approved Huifeng Biochemistry's increased investment in Huifeng Pharmaceutical
from $31,401 to $1,685,990 through an increase in the registered capital of
Huifeng Pharmaceutical from $603,865 to $2,258,454. The acquisition of Huifeng
Pharmaceutical by Huifeng Biochemistry was through a step process increasing
Huifeng Biochemistry's interest in Huifeng Pharmaceutical from 26% to 80.2%.

During 2004, Huifeng Biochemistry's stockholders exchange 100% of their
ownership of Huifeng Biochemistry for 500,000 shares of Northwest under a
reorganization plan. The transfer has been accounted for as a reorganization of
entities under common control as the companies were beneficially owned by
principally identical stockholders and share common management.

On December 20, 2004, pursuant to a Stock Purchase Agreement, a Secured Data
stockholder sold 7,229,601 shares in Secured Data to two Northwest stockholders
for $300,000. On the same date, Secured Data entered into an Agreement and Plan
of Reorganization with the Stockholders of Northwest to exchange 30% of
Northwest's outstanding shares for 80,735,590 shares of Secured Data. In
addition, the Agreement calls for Secured Data to issued a Convertible
Promissory Note for $1,900,000 that is convertible into 10,465,725 (post a one
for eighteen reverse split) shares of Secured Data for the remaining 70% of
Northwest. As of Aug 9, 2005, the Convertible Note has not been exercised.

The merger of Secured Data and Northwest has been recorded as a recapitalization
by Northwest, with Northwest being treated as the continuing entity. The
financial statements have been prepared as if the reorganization had occurred

<PAGE>

retroactively. Secured Data, Northwest, Huifeng Biochemistry, Huifeng
Engineering and Huifeng Pharmaceutical are hereafter referred to as ("the
Company"). The transactions were treated for accounting purposes as a capital
transaction and recapitalization by the accounting acquirer ("Northwest") and as
a reorganization by the accounting acquiree ("Secured Data").

Accordingly, the financial statements include the following:

(1)      The balance sheets as of June 30, 2005 (unaudited) and December 2004
         consist of the net assets of the acquirer at historical cost and the
         net assets of the acquiree at historical cost.

(2)      The statements of operations for the three and six months ended June
         30, 2005 (unaudited) includes the operations of the acquirer for the
         periods presented and the operations of the acquiree from the date of
         the merger.

The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with accounting principles generally accepted in the
United States of America for interim financial information and pursuant to the
rules and regulations of the Securities and Exchange Commission. Accordingly,
they do not include all of the information and footnotes required by generally
accepted accounting principles for complete financial statements.

It the opinion of management, the unaudited condensed consolidated financial
statements contain all adjustments consisting only of normal recurring accruals
considered necessary to present fairly the Company's financial position at June
30, 2005, the results of operations for the three and six months ended June 30,
2005, and cash flows for the six months ended June 30, 2005. The results for the
six months ended June 30, 2005 are not necessarily indicative of the results to
be expected for the entire fiscal year ending December 31, 2005. These financial
statements should be read in conjunction with the Company's annual report on
Form 10-KSB as filed with the Securities and Exchange Commission.

NOTE 2            ACQUISITION

On May 27, 2005 the PRC Government approved Huifeng Biochemistry's increased
investment in Huifeng Pharmaceutical from $31,401 to $1,685,990 through an
increase in the registered capital of Huifeng Pharmaceutical from $603,865 to
$2,258,454. The acquisition of Huifeng Pharmaceutical by Huifeng Biochemistry
was through a step process increasing Huifeng Biochemistry's interest in Huifeng
Pharmaceutical from 26% to 80.2%.

NOTE 3            PRINCIPLES OF CONSOLIDATION

The accompanying condensed consolidated financial statements as of June 30, 2005
(unaudited) include the accounts of Secured Data and its 100% owned subsidiary
Northwest, 100% owned subsidiary Huifeng Biochemistry, 70% owned subsidiary
Huifeng Engineering and 80.2% owned subsidiary Huifeng Pharmaceutical from the
date of its step acquisition on May 27, 2005 to June 30, 2005. The Company
accounts for its investment in Huifeng Pharmaceutical from January 1, 2005 to
May 26, 2005 under the equity method of accounting. Minority interest represents
the minority stockholders' proportionate share of Huifeng Engineering and
Huifeng Pharmaceutical. All significant inter-company balances and transactions
have been eliminated on consolidation.

NOTE 4            USE OF ESTIMATES

The preparation of the financial statements in conformity with general accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amount of assets and liabilities and disclosure of
contingent assets and liabilities at the date of financial statements and the
reported amounts of revenues and expenses during the reporting periods. Actual
results could differ from those estimates.

<PAGE>

NOTE 5            EARNINGS PER SHARE

Basic earnings per share are computed by dividing income available to common
stockholders by the weighted average number common shares outstanding during the
period. Diluted earnings per share is computed similar to basic earnings per
share except that the denominator is increased to include the number of
additional common shares that would have been outstanding if the potential
common shares had been issued and if the additional common shares were dilutive.
There are no potentially dilutive securities for the six months ended June 30,
2005 and 2004.

The weighted average of shares used to compute the diluted earnings per share in
these financial statements (unaudited) would potentially be further diluted by
10,465,725 shares of common stock (post a one for eighteen reverse split) in the
future had the convertible promissory note of $1,900,000 be exercised.

NOTE 6            ACQUISITION OF SUBSIDIARY

On May 27, 2005, the Company's subsidiary - Huifeng Biochemistry completed its
80.2% interest step acquisition of Huifeng Pharmaceutical. Under the purchase
method of accounting, the total purchase price was allocated to Huifeng
Pharmaceutical's net tangible assets based upon the estimated fair values of the
assets as of the date of completion of the acquisition.

A summary of the fair value of net assets of Huifeng Pharmaceutical at the date
of acquisition is as follows:

Current assets                                                      $   582,743
Non-current assets                                                    1,526,118
                                                                    -----------
Total assets                                                          2,108,861
Current liabilities                                                     (10,870)
                                                                    -----------
Net assets acquired                                                   2,097,991

Minority interest                                                      (415,088)
                                                                    -----------
                                                                      1,682,903
Share of pre-acquisition losses prior to becoming a subsidiary              323
                                                                    -----------
                                                                      1,683,226
Goodwill acquired                                                         2,764
                                                                    -----------

Consideration paid                                                  $ 1,685,990
                                                                    -----------

The unaudited pro forma information presents a summary of the results of
operations of the Company assuming the acquisitions of Huifeng Pharmaceutical
occurred at the beginning of each period is as follows:

<TABLE>
<CAPTION>
                               For the Three     For the Three    For the Six      For the Six
                                Months Ended     Months Ended     Months Ended     Months Ended
                               June 30, 2005     June 30, 2004   June 30, 2005     June 30, 2004
                               --------------   --------------   --------------   --------------
<S>                            <C>              <C>              <C>              <C>
Net sales                      $      416,274   $      679,893   $    1,342,812   $    1,213,512

Net income                     $       62,060   $       34,228   $      125,623   $       63,572

Net income per share-diluted   $           --   $           --   $           --   $           --
</TABLE>

<PAGE>

NOTE 7            GOODWILL

<TABLE>
<CAPTION>
                                                                                 2005
                                                                           (Unaudited)      2004
                                                                         ------------    ------------
<S>                                                                      <C>             <C>
Cost of goodwill acquired in step acquisition of a subsidiary            $      2,764    $          -
Amount written off                                                             (2,764)              -
                                                                         ------------    ------------
                                                                         $          -    $          -
                                                                         ------------    ------------
</TABLE>

NOTE 8            LOANS RECEIVABLE

Loans receivable at June 30, 2005 (Unaudited) and December 31, 2004 consisted of
the following:

<TABLE>
<CAPTION>
                                                                   2005
                                                             (Unaudited)          2004
                                                           ------------   ------------

<S>                                                        <C>            <C>
Loan receivable from a third party, interest rate of 12%        181,159             --
     per annum, non-secured, due September 2005

Loan receivable from a third party, interest rate of 10%
     per annum, non-secured, due November 2005                  241,546             --
                                                           ------------   ------------
                                                                422,705             --
                                                           ------------   ------------
</TABLE>

NOTE 9            CONVERTIBLE NOTE PAYABLE

Convertible note payable at June 30, 2005 (unaudited) and December 31, 2004
consisted of the following:

                                               2005
                                         (Unaudited)                    2004
                                --------------------     --------------------

Convertible note payable        $          1,900,000     $          1,900,000
                                --------------------     --------------------

Pursuant to a Convertible Promissory Note, the Company promises to pay to
Stockholders or their registered assigns, the principal sum of $1,900,000 on
June 30, 2005 or such earlier date as the Convertible Note is required or
permitted to be repaid as provided hereunder the maturity date, and to pay
interest to the Holders on the aggregate unconverted and then outstanding
principal amount of this Convertible Note at the rate of 5 % per annum, payable
on the maturity date as set forth herein. Interest shall be calculated on the
basis of a 360 days year and shall accrue on the maturity date. On the maturity
date, the Company may, in its sole discretion, pay the principal sum by issuing
to the Holder 10,465,725 shares of the Company's restricted common stock at
$0.1815 per share, provided a require 1 for 18 reverse stock split of the common
stock has been effected. On June 30, 2005, the Company amended the due date of
the Convertible Promissory Note from June 30, 2005 to December 31, 2005 with all
other terms and conditions set forth in the Note remaining unchanged. As of
August 9, 2005, the Convertible Promissory Note has not been exercised.


NOTE 10    COMMITMENTS AND CONTINGENCIES

      (A)   Employee benefits

            The full time employees of the Company are entitled to employee
            benefits including medical care, welfare subsidies, unemployment
            insurance and pension benefits through a Chinese government mandated
            multi-employer defined contribution plan. The Company is required to

<PAGE>

            accrue for those benefits based on certain percentages of the
            employees' salaries and make contributions to the plans out of the
            amounts accrued for medical and pension benefits. The Chinese
            government is responsible for the medical benefits and the pension
            liability to be paid to these employees.

(B)   Commitments

            The Company occupies office space from a third party under an
            operating lease which expires on March 2006 at a quarterly rental of
            $3,080. Accordingly, for the six months ended June 30, 2005 and
            2004, the Company recognized rental expenses for this space in the
            amount of $6,160 and $6,160 respectively.

            As of June 30, 2005, the Company has outstanding commitments with
            respect to the non-cancelable operating leases, which are due as
            follows:


            2005                   $            6,159
            2006                                3,080
                                   ------------------
                                   $            9,239
                                   ------------------



NOTE 11    STOCKHOLDERS' EQUITY


      (A)   Stock issuances



            On December 20, 2004 the Company entered into an Agreement and Plan
            of Reorganization with Northwest Bio-Technic Inc. ("Northwest") to
            acquire 100% of Northwest equity. The Company issued 80,735,590
            shares in exchange for 30% of Northwest's outstanding shares.



            The Company has authorized up to 5,000,000 shares of preferred stock
            with a par value of $0.001 per share. The preferred stock can be
            issued in various series with varying dividend rates and
            preferences. As of June 30, 2005 there are no issued series of
            shares of preferred stock.



      (B)   Capital contribution


            During the three months ended March 31, 2005, the Company's
            subsidiary Xian Huifeng Biochemistry Joint-Stock Company Limited
            ("Hufeng Biochemistry") declared a contribution of $2,415,459 to be
            used to increase its registered capital.



      (C)   Appropriated retained earnings


            The Company's wholly owned subsidiary, Huifeng Biochemistry is
            required to make appropriations to reserves funds, comprising the
            statutory surplus reserve, statutory public welfare fund and
            discretionary surplus, reserve, based on after-tax net income
            determined in accordance with generally accepted accounting
            principles of the People's Republic of China (the "PRC GAAP").
            Appropriation to the statutory surplus reserve should be at least

<PAGE>

            10% of the after tax net income determined in accordance with the
            PRC GAAP until the reserve is equal to 50% of the entities'
            registered capital. Appropriations to the statutory public welfare
            fund are at 5% to 10% of the after tax net income determined in
            accordance with the PRC GAAP. The statutory public welfare fund is
            established for the purpose of providing employee facilities and
            other collective benefits to the employees and is non-distributable
            other than in liquidation. Appropriations to the discretionary
            surplus reserve are made at the discretion of the Board of
            Directors.


NOTE 12    RELATED PARTY TRANSACTIONS


The Company had advanced funds totaling $258,290 and $62,493 to stockholders as
of June 30, 2005 and December 31, 2004 respectively as short-term, unsecured
loans free of interest payment.

Stockholders had also advanced funds totaling $1,208 and 193,433 to the Company
as of June 30, 2005 and December 31, 2004 respectively as short-term, unsecured
loans free of interest payment.

During the three months ended March 31, 2005, the Company advanced funds
totaling $1,665,459 to its 26% associate, Xian Huifeng Pharmaceutical Co. Ltd,
of which $1,654,589 was advanced for the purpose of increasing, subject to the
PRC Government approval, the Company's investment in the affiliate. On May 27,
2005 the PRC Government approval was obtained and the Company interest in the
affiliate increased from 26% to 80.2%.

<PAGE>

Item 2.  Management's Discussion and Analysis or Plan of Operation.

This report contains forward-looking statements within the meaning of the
federal securities laws. These include statements about our expectations,
beliefs, intentions or strategies for the future, which we indicate by words or
phrases such as "anticipate," "expect," "intend," "plan," "will," "we believe,"
"SCRE believes," "management believes" and similar language. The forward-looking
statements are based on the current expectations of SCRE and are subject to
certain risks, uncertainties and assumptions, including those set forth in the
discussion under "Management's Discussion and Analysis or Plan of Operation".
The actual results may differ materially from results anticipated in these
forward-looking statements. We base the forward-looking statements on
information currently available to us, and we assume no obligation to update
them.

On December 20, 2004, pursuant to the Malone Agreement, Art Malone, Jr.
("Selling Shareholder") sold 7,229,601 shares of the common stock of the Company
for $300,000 (the "Sale") to Zhi Lan Wang and Jun Lin, individuals on the
closing date of December 20, 2004. Such 7,229,601 shares of the common stock of
the Company represented approximately 56.18% of the total outstanding stock of
the Company as of that date.

Immediately thereafter, pursuant to the terms of an Agreement and Plan of
Reorganization dated December 20, 2004 ("Northwest Agreement"), the Company
agreed to purchase all of the outstanding shares of Northwest BioTechnic, Inc.
("NBTI"), a British Virgin Islands corporation (the "Acquisition"). NBTI was
incorporated in the British Virgin Islands on June 25, 2004.

At the time of the Acquisition, NBTI had a total of 500,000 shares issued and
outstanding, 250,000 of which were held by Jing An Wang, and 50,000 each were
held by Xinwen Hou, Zhang Jungi, Wang Bijun, Wang Zhilan, and Wang Xugang (the
"NBTI Shareholders"). Pursuant to the terms of the Northwest Agreement, at the
closing of the Acquisition, the Company delivered the following consideration to
the NBTI Shareholders: (i) 80,735,590 newly-issued shares of the common stock of
the Company (the "Initial NBTI Consideration") in exchange for 30% of the total
outstanding shares of NBTI (such shares of the common stock of the Company
allocated among the NBTI Shareholders on a pro rata basis according to their
respective ownership of NBTI); and (ii) a promissory note (the "Promissory
Note") payable to the NBTI Shareholders for the total amount of $1,900,000, in
exchange for the remaining 70% of the total outstanding shares of NBTI. The
Promissory Note is convertible into 10,465,725 shares of the Company's common
stock (allocated among the NBTI Shareholders on a pro rata basis according to
their respective ownership of NBTI), with such number of shares calculated
assuming the completion of a one-for-eighteen reverse split of the Company's
common stock prior to such conversion. Based on the current ownership of NBTI
shares by the NBTI Shareholders, Jing An Wang would receive 5,232,860 shares of
the Company's common stock upon conversion, and each of Xinwen Hou, Zhang Jungi,
Wang Bijun, Wang Zhilan, and Wang Xugang would receive 1,046,573 shares of the
Company's common stock.

NBTI operates through its wholly owned subsidiary, Huifeng Biochemistry Joint
Stock Company ("Huifeng"), which is a joint venture company established under
the laws of China and is engaged in the production and sales of plant extracts,
biochemical products and pharmaceutical raw products in the PRC.

The exchange was treated as a reverse acquisition for accounting purposes. As
such, the financial information reflected activity subsequent to the acquisition
of the Company and its subsidiaries and financial activity of NBTI prior to the
acquisition. We will continue the business operations conducted by NBTI.



CRITICAL ACCOUNTING POLICIES AND ESTIMATES

We have identified one policy area as critical to the understanding of our
consolidated financial statements. The preparation of our consolidated financial
statements requires management to make estimates and assumptions that affect the

<PAGE>

reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the consolidated financial statements and the
reported amounts of sales and expenses during the reporting periods. With
respect to net realizable value of the Company's accounts receivable and
inventories, significant estimation judgments are made and actual results could
differ materially from these estimates.

The Company does not have any reserves against its accounts receivable or
inventories at June 30, 2005 and 2004. Management's estimation that there are no
reserves is based on the current facts that there are no significant aged
accounts receivable and the current inventory turnover is sufficient to realize
the current carrying value of the inventories. In making their judgment,
management has assumed that there will be continued demand for their products in
the future, thereby maintaining adequate turnover of the inventories.
Additionally, management has assumed that customers will continue to pay their
outstanding invoices timely, and that their customers' financial positions will
not deteriorate significantly in the future, which would result in their
inability to pay their debts to the Company. While the Company's management
currently believes that there is little likelihood that the actual results of
their current estimates will differ materially from its current estimates, if
customer demand for its products decreases significantly in the near future, or
if the financial position of its customers deteriorates in the near future, the
Company could realize significant write downs for slow moving inventories or
uncollectible accounts receivable.

We believe the following is among the most critical accounting policies that
impact our consolidated financial statements. We suggest that our significant
accounting policies, as described in our consolidated financial statements in
the Summary of Significant Accounting Policies, be read in conjunction with this
Management's Discussion and Analysis of Financial Condition and Results of
Operations.

We recognize revenue in accordance with Staff Accounting Bulletin ("SAB") No.
104. All of the following criteria must exist in order for us to recognize
revenue:

      1. Persuasive evidence of an arrangement exists;

      2. Delivery has occurred or services have been rendered;

      3. The seller's price to the buyer is fixed or determinable; and

      4. Collectibility is reasonably assured.

The majority of the Company's revenue results from sales contracts with
distributors and revenue is generated upon the shipment of goods. The Company's
pricing structure is fixed and there are no rebate or discount programs.
Management conducts credit background checks for new customers as a means to
reduce the subjectivity of assuring collectibility. Based on these factors, the
Company believes that it can apply the provisions of SAB 104 with minimal
subjectivity.

RESULTS OF OPERATIONS

THREE MONTHS ENDED JUNE 30, 2005 COMPARED TO THREE MONTHS ENDED JUNE 30, 2004

Revenues, Cost of Revenues and Gross Margin

Revenues for the quarter ended June 30, 2005 were $416,274 a decrease of
$263,619 from $679,893 for same quarter in 2004. Our decreases in sales revenues
in 2004 were mainly attributable to the decrease in our sales of the following
products in second quarter of 2005 against same quarter in 2004:

<TABLE>
<CAPTION>
Product                                      For quarter ended June 30,
                                  --------------------------------------         Increase /
                                        2005                  2004               (Decrease)
--------------------------------  -----------------      ---------------     ---------------
<S>                               <C>                     <C>                <C>
Pharmaceutical intermediates      $        244,691        $     643,203      $     (398,512)
Pharmaceutical material                         93                5,278             (5,185)
Plant Extractive and others                171,490               31,412             140,078

                                  ----------------        -------------      --------------
TOTAL                             $        416,274        $     679,893      $      263,619
                                  ================        =============      ==============
</TABLE>


Cost of revenues for the quarter ended June 30, 2005 were $276,888, a decrease
of $343,088 from $619,976 for the quarter ended June 30, 2004. Compared to the
quarter ended June 30, 2004, the decrease in cost of sales of our products was
because of our decrease in sales revenue in 2005 of the following products
against 2004:

<TABLE>
<CAPTION>
Product                                                For quarter ended June 30,
                                                 ---------------------------------------         Increase /
                                                       2005                    2004             (Decrease)
--------------------------------------------     ------------------      ---------------     ---------------
<S>                                              <C>                     <C>                 <C>
Pharmaceutical intermediates                     $         143,664       $      575,962      $    (432,298)
Pharmaceutical material                                        103                4,434             (4,331)
Plant Extractive and others                                133,121               39,580              93,541

                                                 ------------------      ---------------     ---------------
TOTAL                                            $         276,888       $      619,976      $    (343,088)
                                                 ==================      ===============     ===============
</TABLE>


The increase in cost of sales of our products was not in the same proportion as
our increase in sales revenue because our profit margin improved in the three
months ended June 30, 2005 as compared to same period in 2004. Our gross profit
margin for 2005 improved from 8.8% in the second quarter of 2004 to 33.5% in the
same quarter in 2005. The major reason for the increase in profit margin was
because of an increase in overseas sales in the three months ended June 30, 2005
as compared to the same period in 2004.

Gross margin for the quarter ended June 30, 2005 was $139,386, an increase of
$79,469 from $59,917 for the period ended June 30, 2004.

General and Administrative Expenses

General and Administrative expenses totaled $45,674 for the three months ended
June 30, 2005, an increase of $39,900 from $5,774 for the three months ended
June 30, 2004. The increase in general and administrative expenses was mainly
due to an increase in general and administrative expenses in Huifeng and SCRE as
a result of an increase in business activities and the listing of the Company on
the Over The Counter Bulletin Board. In the three months ended June 30, 2005,
there was an increase in consultancy fee of approximately $3,000, audit fee of
$20,000 and miscellaneous expenses of approximately $16,900, which did not
happen in the same quarter last year.

<PAGE>

Selling and Distribution Expenses

Selling and distribution expenses totaled $32,311 for the three months ended
June 30, 2005, an increase of $23,830 from $8,481 for the three months ended
June 30, 2004. The Company has increased its expenses in sales and distribution
with sales revenue increasing in order to support the direct selling activities
to industrial customers. In the three months ended June 30, 2005, there was an
increase in salaries of approximately $5,500, transportation expenses of $12,000
and other expenses of $6,330.


SIX MONTHS ENDED JUNE 30, 2005 COMPARED TO SIX MONTHS ENDED JUNE 30, 2004

Revenues, Cost of Revenues and Gross Margin

Revenues for the six months ended June 30, 2005 were $1,342,812 an increase of
$129,300 from $1,213,512 for same period in 2004. Our increase in sales revenues
in 2005 were mainly attributable to the increase in our sales of the following
products in the first six months of 2005 against same period in 2004:

<TABLE>
<CAPTION>
Product                                                       Six months ended June 30,
                                                  --------------------------------------        Increase /
                                                        2005                 2004               (Decrease)
--------------------------------------------      -----------------      ---------------     ---------------
<S>                                               <C>                    <C>                 <C>
Pharmaceutical intermediates                      $      1,144,021       $    1,174,189      $     (30,168)
Pharmaceutical material                                        227                5,278             (5,051)
Plant Extractive and others                                198,564               34,045            164,519
                                                  -----------------      ---------------     ---------------
TOTAL                                             $      1,342,812       $    1,213,512      $     129,300
                                                  =================      ===============     ===============
</TABLE>


Cost of revenues for the six months ended June 30, 2005 were $1,093,703, an
increase of $11,641 from $1,082,062 for the six months ended June 30, 2004.
Compared to the six months ended June 30, 2004, the increase in cost of sales of
our products was because of our increase in sales revenue in 2005 of the
following products against 2004:

<TABLE>
<CAPTION>
Product                                                       Six months ended June 30,
                                                 ---------------------------------------        Increase /
                                                        2005                   2004             (Decrease)
--------------------------------------------     -----------------       --------------      --------------
<S>                                              <C>                     <C>                 <C>
Pharmaceutical intermediates                     $         884,797       $    1,020,651      $     (135,854)
Pharmaceutical material                                        206                4,434              (4,228)
Plant Extractive and others                                208,700               56,977             151,723
                                                 ------------------      ---------------     ---------------
TOTAL                                            $       1,093,703       $    1,082,062      $       11,641
                                                 ==================      ===============     ===============
</TABLE>

The increase in cost of sales of our products was not in the same proportion as
our increase in sales revenue because our profit margin improved in the six
months ended June 30, 2005 as compared to same period in 2004. Our gross profit

<PAGE>

margin for 2005 improved from 10.8% in the first six months of 2004 to 18.6% in
the same period in 2005. The major reason for the increase in profit margin was
because of an increase in overseas sales in the six months ended June 30, 2005
as compared to the same period in 2004.

Gross margin for the six months ended June 30, 2005 was $249,109, an increase of
$117,659 from $131,450 for the period ended June 30, 2004.

General and Administrative Expenses

General and Administrative expenses totaled $87,750 for the six months ended
June 30, 2005, an increase of $73,176 from $14,574 for the six months ended June
30, 2004. The increase in general and administrative expenses was mainly due to
an increase in general and administrative expenses in Huifeng and SCRE as a
result of an increase in business activities and the listing of the Company on
the Over The Counter Bulletin Board. For the six months ended June 30, 2005,
there was an increase in consulting fees of approximately $7,000, audit fees of
$40,000 and miscellaneous expenses of approximately $26,176, none of which
occurred in the same period in 2004.

Selling and Distribution Expenses

Selling and distribution expenses totaled $48,705 for the six months ended June
30, 2005, an increase of $32,702 from $16,003 for the six months ended June 30,
2004. The Company has increased its expenses in sales and distribution with
sales revenue increasing in order to support the direct selling activities to
industrial customers. In the six months ended June 30, 2005, there was an
increase in salaries of approximately $7,500, transportation expenses of
$15,000, expenses for meeting and seminar of $5,500 and other expenses of
$4,702.

Liquidity and Capital Resources

Cash

Our cash balance amounted to $343,758 at June 30, 2005.

In the six months ended June 30, 2005, our cash provided by operating activities
totaled $149,393, mainly due to our net income for the period of $104,499, an
increase in accounts receivable in the six-month period, which totaled $358,014
and increase in inventory of $129,065. Increase in inventory and accounts
receivable were as a result of our increase in operating scale and the Company
required more working capital. In the six months ended June 30, 2005, cash flow
used in investing activities totaled $1,773,674, out of which $1,577,877 was
spent on the purchase of property and equipment held by a subsidiary. Cash flow
provided by financing activities totaled $1,800,528.

The Company is currently funding its operations from our income from operations.

Working Capital

Our working capital amounted to $1,142,928 at June 30, 2005.

INFLATION

Inflation has not had a material impact on our business.

CURRENCY EXCHANGE FLUCTUATIONS

All of the Company's revenues and a majority of the expenses in the first six
months of 2005 were denominated primarily in Renminbi ("RMB"), the currency of
The People's Republic of China. There can be no assurance that RMB-to-U.S.

<PAGE>

dollar exchange rates will remain stable. A devaluation of the RMB relative to
the U.S. dollar would adversely affect our business, financial condition and
results of operations. We do not engage in currency hedging. On July 22, 2005,
Renminbi rose about 2 percent against the U.S. dollar to a new exchange rate of
8.11 RMB to 1 U.S. dollar.


Item 3.  Controls and Procedures

The Company maintains disclosure controls and procedures that are designed to
ensure that information required to be disclosed in the Company's Exchange Act
reports is recorded, processed, summarized and reported within the time periods
specified in the SEC's rules and forms, and that such information is accumulated
and communicated to the Company's management, including its Chief Executive
Officer and Chief Financial Officer, as appropriate, to allow timely decisions
regarding required disclosure based closely on the definition of "disclosure
controls and procedures" in Rule 13a-14(c). The Company's disclosure controls
and procedures are designed to provide a reasonable level of assurance of
reaching the Company's desired disclosure control objectives. In designing and
evaluating the disclosure controls and procedures, management recognized that
any controls and procedures, no matter how well designed and operated, can
provide only reasonable assurance of achieving the desired control objectives,
and management necessarily was required to apply its judgment in evaluating the
cost-benefit relationship of possible controls and procedures. The Company's
certifying officer has concluded that the Company's disclosure controls and
procedures are effective in reaching that level of assurance.

As of the end of the period of this report, the Company carried out an
evaluation, under the supervision and with the participation of the Company's
management, including the Company's Chief Executive Officer and the Company's
Chief Financial Officer, of the effectiveness of the design and operation of the
Company's disclosure controls and procedures. Based on the foregoing, the
Company's Chief Executive Officer and Chief Financial Officer concluded that the
Company's disclosure controls and procedures were effective.

There have been no changes during the period covered by this report in the
Company's internal controls or in other factors that has materially affected, or
is reasonably likely to materially affect, the Company's internal control over
financial reporting.



PART II.  OTHER INFORMATION


Item 1.  Legal Proceedings:

We are currently not involved in any litigation that we believe could have a
material adverse effect on our financial condition or results of operations.
There is no action, suit, proceeding, inquiry or investigation before or by any
court, public board, government agency, self-regulatory organization or body
pending or, to the knowledge of the executive officers of our Company or any of
our subsidiaries, threatened against or affecting the Company, our common stock,
any of our subsidiaries or of our Company's or our Company's subsidiaries'
officers or directors in their capacities as such, in which an adverse decision
could have a material adverse effect.

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds:

None.

Item 3.  Defaults Upon Senior Securities:

None.

<PAGE>

Item 4. Submission of Matters to a Vote of Security Holders:

On March 23, 2005, the Board of Directors unanimously approved and ratified a
1:18 reverse split (the "Reverse Split") of the Company's issued and outstanding
common stock and an amendment (the "Amendment") to its Articles of Incorporation
changing the name of the Company to "Huifeng Bio-pharmaceutical Technology
Inc.", subject to the approval of the Company's stockholders. The record date
established by the Board for purposes of determining the number of outstanding
shares of voting stock entitled to vote on the Reverse Split and the Amendment
was March 23, 2005 (the "Record Date"). On the Record Date, stockholders owning
53,850,640 shares of Common Stock, or approximately 57.5% of the issued and
outstanding shares of Common Stock, approved the Reverse Split and the Amendment
by action taken without a meeting in accordance with Nevada law. No further vote
of our stockholders was required.

As a result, the Company filed a preliminary information statement pursuant to
Section 14(c) of the Securities Exchange Act of 1934 on March 23, 2005 in
connection with the approval by a majority of the stockholders of (i) an
amendment to its Articles of Incorporation effecting the Reverse Split and (ii)
the Amendment.

On the effective date of the Reverse Split the number of issued and outstanding
shares of common stock of the Company will be reduced from a total of 93,604,958
shares which were outstanding on the Record Date, to approximately 5,200,275
shares.

When filed with the Nevada Secretary of State, the Amendment will change the
name of the Company to "Huifeng Bio-pharmaceutical Technology Inc."

However, as of the date of this filing, this preliminary information statement
was still not approved by the Securities and Exchange Commission. On July 12,
2005, the Company announced that still has not received clearance from the
United States Securities and Exchange Commission to send notification to its
shareholders to describe the Company's transaction with Secured Data, Inc., a
U.S. public company traded on the OTC Bulletin Board. This transaction was
effected in December 2004. The SEC has informed the Company's legal counsel that
it will not approve the mailing of an Information Statement to shareholders
until all comments from the SEC on the Company's 10-KSB filing are adequately
addressed by the Company. The Company cannot predict with any degree of
certainty when the SEC will clear all comments and allow the mailing of the
Company's Information Statement.

Item 5. Other Information:

None

Item 6.  Exhibits and Reports on Form 8-K

      (a)   Exhibits

3.1.  Articles of Incorporation (1)
3.2   ByLaws (1)
3.3   Certificate of Amendment to Articles of Incorporation (2)
10.1  Amended Agreement and Plan of Reorganization dated July 13, 2004 (3)
10.2  Agreement and Plan of Reorganization dated as of December 20, 2004 by and
      among Secured Data, Inc., Northwest Bio-Technic Inc., and the shareholders
      of Northwest Bio- Technic Inc.; and Convertible Promissory Note (3)
10.3. Amendment No. 1 to the Convertible Promissory Note Due June 30, 2005 (4)
31.1  Sarbanes Oxley Section 302 Certification
31.2  Sarbanes Oxley Section 302 Certification

<PAGE>

32.1  Sarbanes Oxley Section 906 Certification
32.2  Sarbanes Oxley Section 906 Certification
99.1  Code of Ethics (2)

(1)  Incorporated by Reference from the registration statement on form SB-2
     filed on or about July 28, 2000.

(2)  Incorporated by Reference from the registrant's quarterly report on Form
     10-qsb for the fiscal quarter ended March 31, 2004 filed on May 17, 2004.

(3)  Incorporated by Reference from registrant's current report on Form 8-k
     filed on August 11, 2004.
(4)  Incorporated by reference from the Current Report on Form 8-K filed on or
     about July 7, 2005.

      (b)   The following reports on Form 8-K were filed:
            o     February 4, 2005 to report the resignation of Art Malone as a
                  director.
            o     March 11, 2005 to report the Transaction.
            o     March 18, 2005 to report the change in accountant.
            o     April 7, 2005 to report the change in accountant.
            o     April 22, 2005 to report the change in accountant.
            o     May 12, 2005 to report the Transaction.
            o     June 20, 2005 to report non-reliance on previously issued
                  financial statements.
            o     June 22, 2005 to report non-reliance on previously issued
                  financial statements.
            o     July 7, 2005 to report the amending of the Promissory Note.

<PAGE>

                                   SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, as amended, the registrant has duly caused this Report to be signed
on its behalf by the undersigned, thereunto duly authorized this 12th day of
August 2005.


                                                  SECURED DATA, INC.

                                            By:   /s/ JING AN WANG
                                                  ----------------------
                                                  Jing An Wang
                                                  Chief Executive Officer